Reviva Pharmaceuticals (NASDAQ:RVPH) Shares Down 13.5% – What’s Next?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) dropped 13.5% during trading on Wednesday . The company traded as low as $0.4001 and last traded at $0.45. Approximately 18,491 shares traded hands during trading, a decline of 96% from the average daily volume of 413,993 shares. The stock had previously closed at $0.52.

Analyst Upgrades and Downgrades

RVPH has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Maxim Group cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Stock Down 13.5%

The stock’s 50-day moving average price is $0.58 and its 200-day moving average price is $2.03. The company has a market capitalization of $5.90 million, a price-to-earnings ratio of -0.11 and a beta of 0.47.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, equities research analysts anticipate that Reviva Pharmaceuticals Holdings, Inc. will post -2.96 EPS for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Large investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new position in Reviva Pharmaceuticals in the first quarter valued at about $58,000. Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the period. XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals during the 2nd quarter valued at about $31,000. Armistice Capital LLC bought a new position in shares of Reviva Pharmaceuticals in the 2nd quarter valued at about $1,026,000. Finally, Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals in the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.